Three Bone Density Stories Worth Knowing About

Three pieces of bone news have landed recently that deserve your attention. One reinforces what already works for severe osteoporosis. One gives a category of supplement a serious upgrade in legitimacy. And one is a “miracle cure” headline doing the rounds that you should treat with cautious interest, not excitement.

Here’s what each actually says.

Strong to the Bone is for those who want real, evidence-based answers on bone health. Not subscribed yet? Join free below. Already a reader? Upgrade to paid and get the full protocols, training plans, and clinical depth.

Not ready to upgrade? Forward this to one person who’d benefit. The list grows by referral, and so does the impact.

1. Romosozumab in older women: more evidence it works

The January 2026 issue of Bone published a real-world study of romosozumab (brand name Evenity) in 186 postmenopausal women, median age 76, recruited across two Belgian clinics and one Italian clinic. Most had suffered a major osteoporotic fracture within the previous two years. Thirty-five per cent were over 80. Sixteen per cent were over 85.

After 12 months on the standard course, bone mineral density rose by an average of +9.16% at the lumbar spine and +3.00% at the total hip. The gains held up in both treatment-naïve patients and those who had been on other osteoporosis drugs previously. Response was independent of age.

For context, romosozumab is a once-monthly injection that does something most osteoporosis drugs cannot. It builds bone while simultaneously slowing bone loss. It is reserved for high-fracture-risk patients because of cost and because it carries an FDA black box warning for cardiovascular events, although recent observational data has begun to question whether that warning is warranted. It should not be started within a year of a heart attack or stroke.

If you, your mother, or your grandmother has established osteoporosis and a recent fracture, this study is a strong vote of confidence in romosozumab for the over-75 group, where the evidence has historically been thinner. It is a conversation to have with a rheumatologist or endocrinologist, not a self-prescription.

2. Collagen peptides: the category just got a real meta-analysis

On 4 February 2026, Examine.com published a research summary of a meta-analysis covering 17 randomised controlled trials, one observational study, and two experimental trials. The verdict: 5 g per day of specific bioactive collagen peptides improved bone mineral density at clinically relevant sites (lumbar spine and femoral neck) in people with osteopenia and osteoporosis, compared with placebo. Standardised mean differences sat between 0.40 and 0.58, a moderate but real effect, and the signal was strongest when collagen was paired with calcium and vitamin D.

This essentially vindicates the König et al. 2018 trial published in Nutrients, which gave 131 postmenopausal women either 5 g of specific collagen peptides or placebo for 12 months and found significant BMD gains at the spine and femoral neck, alongside a rise in P1NP (a blood marker of bone formation).

Collagen peptides have spent years in the “promising but unproven” pile. They have now moved into “modest but real, especially as an adjunct.” If you already take calcium and vitamin D and you have low bone density, adding 5 g of a specific bioactive collagen peptide (the trials used Bodybalance/Fortibone from Gelita, not generic protein powder) is a low-risk, evidence-supported addition. It is not a replacement for resistance training or osteoporosis medication. It is an extra lever.

3. The GPR133 “bone switch”: interesting, but years away

You may have seen headlines in early April about a “newly discovered bone switch that could stop osteoporosis.” The underlying paper, published in Signal Transduction and Targeted Therapy (June 2025, DOI: 10.1038/s41392-025-02291-y) by researchers at the University of Leipzig, identified a receptor called GPR133 on bone-forming osteoblasts. They then designed a small molecule called AP503 that activates this receptor. In mice, daily AP503 increased bone volume, improved trabecular architecture, and boosted mechanical strength.

This is interesting science. It is also entirely preclinical. There are no human trials. No safety data. No dose-finding in people. A drug discovery pipeline typically runs 10–15 years from this stage to a prescription. Even an optimistic timeline puts AP503 well into the 2030s, and most preclinical hits never make it to market at all.

Put it in the “watch this space” file. Do not delay starting resistance training, or talking to your doctor about treatment, because something better might be coming. The most useful interventions for your bones are still the ones already available to you.

The bigger pattern

Step back and the three stories tell the same one. We already have things that work for bones: heavy resistance training, impact loading, adequate protein and calcium, vitamin D, and for high-risk patients, drugs like romosozumab. New research is filling in details (collagen as an adjunct), validating existing tools in harder-to-treat populations (older women on romosozumab), and pointing at future possibilities (GPR133).

What it is not doing is rewriting the basics. Lift heavy. Land hard. Eat enough protein. Get your DEXA scan. The headlines change. The fundamentals don’t.

If you found this useful, the deep-dive that landed in paid subscribers’ inboxes this week is on weighted vests: when they actually work for bone, when they don’t, and a short home program you can run from your living room. Upgrade in the menu above.